Novo Nordisk A/S
Solid glp-1 derivative compositions for oral administration
Last updated:
Abstract:
The present invention relates to solid compositions for oral administration comprising (i) a GLP-1 derivative and the SGLT2 inhibitor dapagliflozin or (ii) a GLP-1 derivative and a salt of NAC in combination with an SGLT2 inhibitor.
Status:
Grant
Type:
Utility
Filling date:
11 Jun 2018
Issue date:
9 Nov 2021